ARTICLES BY SUZANNE ELVIDGE
The Sangamo And TxCell Story: How Two Companies Built A Deal
What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.
IO Building A New Future For Cancer Treatment
A primer on immuno-oncology and what’s next for this promising field of cancer treatments.
Combatting Unproven Cell And Gene Therapies Through Regulation And Education
According to the inaugural annual report from the International Society for Cell and Gene Therapy (ISCT), the number of CGTs with marketing authorization increased by 45 percent between 2015 and September 2018.
Deal Building From Testing The Water To Hitting The Market
The story of how Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce the Big Pharma's CAR-T cell therapy Kymriah.